NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION

摘要

The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

主权项

1. A compound represented by the formula:R11 is selected from:
a) R11, where is selected from:
1) Hydrogen;2) Deuterium;3) C1-C8 alkyl;4) Substituted C1-C8 alkyl;5) C2-C8 alkenyl;6) Substituted C2-C8 alkenyl;7) C2-C8 alkynyl;8) Substituted C2-C8 alkynyl;9) C3-C12 cycloalkyl;10) Substituted C3-C12 cycloalkyl;11) Aryl;12) Substituted aryl;13) Heterocycloalkyl;14) Substituted heterocycloalkyl;15) Heteroaryl; or16) Substituted heteroaryl; b) —C(O)N(R12)(R13), where R12 and R13 are independently selected from R11 and R11 is as previously defined or R12 and R13 combined together with the N which attached to is substituted or unsubstituted heterocycloalkyl; c) R14, where R14 is selected from:
1) -M-R11, where R11 is as previously defined and M is selected from:
i. C1-C8 alkylene;ii. Substituted C1-C8 alkylene;iii. C2-C8 alkenylene;iv. Substituted C2-C8 alkenylene;v. C2-C8 alkynylene;vi. Substituted C2-C8 alkynylene;vii. C3-C12 cycloalkylene;viii. Substituted C3-C12 cycloalkylene;2) -M-NR15R11, where R15 is R11 or R15 and R11 combined together with the N which attached to is substituted or unsubstituted heterocycloalkyl, M is as previously defined;3) -M-S(O)mR11, where m=0, 1, or 2; M and R11 are as previously defined;4) -M-OR11, where M and R11 are as previously defined;5) -M-C(O) R16, where M is as previously defined and R16 is selected from:
i. C1-C8 alkyl;ii. Substituted C1-C8 alkyl;iii. C2-C8 alkenyl;iv. Substituted C2-C8 alkenyl;v. C2-C8 alkynyl;vi. Substituted C2-C8 alkynyl;vii. C3-C12 cycloalkyl; andviii. Substituted C3-C12 cycloalkyl;6) -M-OC(O) R16, where M and R16 are as previously defined;7) -M-OC(O)O R16, where M and R16 are as previously defined;8) -M-NR17C(O) R16, where R17 is R11, M and R16 are as previously defined;9) -MNR17C(O)O R16, where R17, M and R16 are as previously defined;10) -M-C(O)NR17 R11, where R17, M and R11 are as previously defined;11) -M-C(O)N(R17)—OR11, where R17, M and R11 are as previously defined;12) -M-OC(O)NR17 R11, where R17, M and R11 are as previously defined;13) -M-NR17C(O)NR16 R11, where M, R11, R17 and R16 are as previously defined or R16 and R11 combined together with the N which attached to is substituted or unsubstituted heterocycloalkyl;14) -M-C(S)S R11, where M and R11 are as previously defined;15) -M-OC(S)S R16, where M and R16 are as previously defined;16) -M-NR17C(O)S R16, where M, R17 and R16 are as previously defined;17) -M-SC(O)NR17 R11, where M, R11 and R17 are as previously defined or R17 and R11 combined together with the N which attached to is substituted or unsubstituted heterocycloalkyl;18) -M-CH═N—O R11, where M and R11 are as previously defined;19) -M-CH═N—NR17 R11, where M, R11 and R17 are as previously defined or R17 and R11 combined together with the N which attached to is substituted or unsubstituted heterocycloalkyl;A is R1 and R1 is notR2, R3 and R4 are independently selected from: hydrogen or methyl.